Propanc Biopharma, Inc. 是一家處於研發階段的醫療保健公司,從事癌症治療的研究與開發。該公司專注於為患有胰腺癌、卵巢癌和結直腸癌的患者開發新型癌症治療方法。公司開發了一種合理複合的抗癌化合物配方,這些化合物共同發揮多種作用,旨在控制或防止腫瘤復發和在體內擴散。其主要產品候選藥物PRP是該配方的一種變體,包含前酶——酶的非活性前體。PRP是一種基於胰腺前酶配方的長期療法,用於防止腫瘤復發和轉移。PRP是一種專利配方,由兩種以前酶以協同比例混合組成。PRP目前處於臨床前開發階段。其藥物研發管線還包括POP1。
PPCB stock price ended at $0.22 on 星期二, after rising 4.76%
On the latest trading day Feb 17, 2026, the stock price of PPCB rose by 4.76%, climbing from $0.24 to $0.22. Throughout the session, the stock experienced a volatility of 33.33%, with prices fluctuating between a daily low of $0.18 and a high of $0.24. Alongside this price increase, trading volume also rose by 407.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.1M shares were traded, amounting to a market value of approximately $2.9M.